Cristiana Tanase

Prof. Dr. Cristiana Tanase

Victor Babes National Institute
+2
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
SMSimona Mihai
Simona Mihai
ECElena Codrici
Elena Codrici
IPIonela Daniela Popescu
Ionela Daniela Popescu
AEAna-Maria Enciu
Ana-Maria Enciu
LALucian Albulescu
Lucian Albulescu
CTCristiana Tanase
Cristiana Tanase
Persistent, low-grade inflammation is now considered a hallmark feature of chronic kidney disease (CKD), being involved in the development of all-cause mortality of these patients. Although substantial improvements have been made in clinical care, CKD remains a major public health burden, affecting 10–15% of the population, and its prevalence is constantly growing. Due to its insidious nature, CKD is rarely diagnosed in early stages, and once developed, its progression is unfortunately irreversible. There are many factors that contribute to the setting of the inflammatory status in CKD, including increased production of proinflammatory cytokines, oxidative stress and acidosis, chronic and recurrent infections, altered metabolism of adipose tissue, and last but not least, gut microbiota dysbiosis, an underestimated source of microinflammation. In this scenario, a huge step forward was made by the increasing progression of omics approaches, specially designed for identification of biomarkers useful for early diagnostic and follow-up. Recent omics advances could provide novel insights in deciphering the disease pathophysiology; thus, identification of circulating biomarker panels using state-of-the-art proteomic technologies could improve CKD early diagnosis, monitoring, and prognostics. This review aims to summarize the recent knowledge regarding the relationship between inflammation and CKD, highlighting the current proteomic approaches, as well as the inflammasomes and gut microbiota dysbiosis involvement in the setting of CKD, culminating with the troubling bidirectional connection between CKD and renal malignancy, raised on the background of an inflammatory condition.

6 September 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
DSDiana Stan
Diana Stan
AEAna-Maria Enciu
Ana-Maria Enciu
AMAndreea Lorena Mateescu
Andreea Lorena Mateescu
AIAndreea Cristina Ion
Andreea Cristina Ion
ABAriana Cristina Brezeanu
Ariana Cristina Brezeanu
CTCristiana Tanase
Cristiana Tanase
Due to the increasing prevalence of life-threatening bacterial, fungal and viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compunds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable compounds for this task are usually derived from natural sources (animal, plant or even microbial). In this review article, the latest and most promising natural compounds used to combat bacteria, filamentous fungi and viruses are presented and evaluated. These include plant extracts, essential oils, small antimicrobial peptides of animal origin, bacteriocins and various groups of plant compounds (triterpenoids; alkaloids; phenols; flavonoids) with antimicrobial and antiviral activity. Data are presented on the inhibitory activity of each natural antimicrobial substance and on the putative mechanism of action against bacterial and fungal strains. The results show that among the bioactive compounds studied, triterpenoids have significant inhibitory activity against coronaviruses, but flavonoids have also been shown to inhibit SARS-COV-2. The last chapter is devoted to nanocarriers used to improve stability, bioavailability, cellular uptake/internalization, pharmacokinetic profile and reduce toxicity of natural compunds. There are a number of nanocarriers such as liposomes, drug delivery microemulsion systems, nanocapsules, solid lipid nanoparticles, polymeric micelles, dendrimers, etc. However, some of the recent studies have focused on the incorporation of natural substances with antimicrobial/antiviral activity into polymeric nanoparticles, niosomes and silver nanoparticles (which have been shown to have intrinsic antimicrobial activity). The natural antimicrobials isolated from animals and microorganisms have been shown to have good inhibitory effect on a range of pathogens, however the plants remain the most prolific source. Even if the majority of the studies for the biological activity evaluation are in silico or in vitro, their internalization in the optimum nanocarriers represents the future of “green therapeutics” as shown by some of the recent work in the field.

24 June 2013 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
Radu AlbulescuRadu Albulescu
Radu Albulescu
ECElena Codrici
Elena Codrici
IPIonela Daniela Popescu
Ionela Daniela Popescu
SMSimona Mihai
Simona Mihai
LNLaura Georgiana Necula
Laura Georgiana Necula
CTCristiana Tanase
Cristiana Tanase
Inflammation represents the immune system response to external or internal aggressors such as injury or infection in certain tissues. The body’s response to cancer has many parallels with inflammation and repair; the inflammatory cells and cytokines present in tumours are more likely to contribute to tumour growth, progression, and immunosuppression, rather than in building an effective antitumour defence. Using new proteomic technology, we have investigated serum profile of pro- (IL-1β, IL-6, IL-8, IL-12, GM-CSF, and TNF-α) and anti-inflammatory cytokines (IL-4, IL-10), along with angiogenic factors (VEGF, bFGF) in order to assess tumoural aggressiveness. Our results indicate significant dysregulation in serum levels of cytokines and angiogenic factors, with over threefold upregulation of IL-6, IL-1β, TNF-α, and IL-10 and up to twofold upregulation of VEGF, FGF-2, IL-8, IL-2, and GM-CSF. These molecules are involved in tumour progression and aggressiveness, and are also involved in a generation of disease associated pain.

1 January 2016 in Stem Cells International
Verified
Journal Article
Open access
PDF file
ECElena Codrici
Elena Codrici
AEAna-Maria Enciu
Ana-Maria Enciu
IPIonela-Daniela Popescu
Ionela-Daniela Popescu
SMSimona Mihai
Simona Mihai
CTCristiana Tanase
Cristiana Tanase
Malignant gliomas are aggressive brain tumors with limited therapeutic options, possibly because of highly tumorigenic subpopulations of glioma stem cells. These cells require specific microenvironments to maintain their “stemness,” described as perivascular and hypoxic niches. Each of those niches induces particular signatures in glioma stem cells (e.g., activation of Notch signaling, secretion of VEGF, bFGF, SDF1 for the vascular niche, activation of HIF2α, and metabolic reprogramming for hypoxic niche). Recently, accumulated knowledge on tumor‐associated macrophages, possibly delineating a third niche, has underlined the role of immune cells in glioma progression, via specific chemoattractant factors and cytokines, such as macrophage‐colony stimulation factor (M‐CSF). The local or myeloid origin of this new component of glioma stem cells niche is yet to be determined. Such niches are being increasingly recognized as key regulators involved in multiple stages of disease progression, therapy resistance, immune‐escaping, and distant metastasis, thereby substantially impacting the future development of frontline interventions in clinical oncology. This review focuses on the microenvironment impact on the glioma stem cell biology, emphasizing GSCs cross talk with hypoxic, perivascular, and immune niches and their potential use as targeted therapy.

14 July 2015 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
Radu AlbulescuRadu Albulescu
Radu Albulescu
CTCristiana Tanase
Cristiana Tanase
ECElena Codrici
Elena Codrici
DPDaniela I. Popescu
Daniela I. Popescu
Sanda Maria CretoiuSanda Maria Cretoiu
Sanda Maria Cretoiu
LPLaurentiu M. Popescu
Laurentiu M. Popescu
Telocytes (TCs) are interstitial cells that are present in numerous organs, including the heart interstitial space and cardiac stem cell niche. TCs are completely different from fibroblasts.TCs release extracellular vesicles that may interact with cardiac stem cells (CSCs)viaparacrine effects. Data on the secretory profile ofTCs and the bidirectional shuttle vesicular signalling mechanism betweenTCs andCSCs are scarce. We aimed to characterize and understand thein vitroeffect of theTCsecretome onCSCfate. Therefore, we studied the protein secretory profile using supernatants from mouse cultured cardiacTCs. We also performed a comparative secretome analysis using supernatants from rat cultured cardiacTCs, a pureCSCline andTCs‐CSCs in co‐culture using (i) high‐sensitivity on‐chip electrophoresis, (ii) surface‐enhanced laser desorption/ionization time‐of‐flight mass spectrometry and (iii) multiplex analysis by Luminex‐xMAP. We identified several highly expressed molecules in the mouse cardiacTCsecretory profile: interleukin (IL)‐6,VEGF, macrophage inflammatory protein 1α (MIP‐1α),MIP‐2 andMCP‐1, which are also present in the proteome of rat cardiacTCs. In addition, rat cardiacTCs secrete a slightly greater number of cytokines,IL‐2,IL‐10,IL‐13 and some chemokines like,GRO‐KC. We found thatVEGF,IL‐6 and some chemokines (all stimulated byIL‐6 signalling) are secreted by cardiacTCs and overexpressed in co‐cultures withCSCs. The expression levels ofMIP‐2 andMIP‐1α increased twofold and fourfold, respectively, whenTCs were co‐cultured withCSCs, while the expression ofIL‐2 did not significantly differ betweenTCs andCSCs in mono culture and significantly decreased (twofold) in the co‐culture system. These data suggest that theTCsecretome plays a modulatory role in stem cell proliferation and differentiation.

30 September 2009 in Translational Research
Verified
Journal Article
Closed access
MCMihaela Chivu
Mihaela Chivu
SDSimona O. Dima
Simona O. Dima
CSCosmin I. Stancu
Cosmin I. Stancu
CDCamelia Dobrea
Camelia Dobrea
VUValentina Uscatescu
Valentina Uscatescu
IPIrinel Popescu
Irinel Popescu